DNA-Guided heart drug choice may save lives in coronary artery disease
NCT ID NCT06665919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether using a person's genetic information to choose their blood-thinning medication (clopidogrel or an alternative) leads to better outcomes after a heart procedure. 283 adults with chronic coronary artery disease who had a stent placed were split into two groups: one received standard care, and the other had their treatment guided by a genetic test. The goal was to see if the genetic approach reduced deaths, heart attacks, and other heart-related events in real-world practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVERSE CARDIAC EVENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
1st University Clinic of the Tbilisi State Medical University
Tbilisi, Georgia
-
Cardio Expert Ltd., Clinic Cardio
Tbilisi, Georgia
-
T. Oragvelidze Cardiology Center
Tbilisi, Georgia
-
Tbilisi Institute of Medicine
Tbilisi, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?
- Can a higher dose of adenosine sharpen heart scans?